EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pirfenidone as a novel cardiac protective treatment

Alberto Aimo iD, Giosafat Spitaleri, Giorgia Panichella, Josep Lupón, Michele Emdin, Antoni Bayes-Genis

Heart Failure Reviews · 2022-03 · 27 (2) · 525-532

DOI: 10.1007/s10741-021-10175-w ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Heart Failure Reviews, online erschienen am 20.10.2021. Verfasst von Alberto Aimo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy. a.aimo@santannapisa.it. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Pyridones. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scuola Superiore Sant'Anna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myocardial fibrosis is a common feature of several heart diseases. The progressive deposition of extracellular matrix due to a persistent injury to cardiomyocytes may trigger a vicious cycle that leads to persistent structural and functional alterations of the myocardium. Some drugs (like renin–angiotensin–aldosterone system inhibitors) have been shown to reduce extracellular matrix deposition, but no primarily anti-fibrotic medications are currently used to treat patients with heart failure (HF). Pirfenidone is an oral antifibrotic agent approved for the treatment of idiopathic pulmonary fibrosis. Although its exact mechanism of action is not fully understood, pirfenidone might reduce the expression of profibrotic factors such as transforming growth factor-β (TGF-β), and proinflammatory cytokines, like tumor necrosis factor-α (TNF-α), interleukin (IL)-4, and IL-13, which could modulate the inflammatory response and inhibit collagen synthesis in lung tissue. There is some evidence that pirfenidone has antifibrotic activity in various animal models of cardiac disease. Furthermore, the positive results of the PIROUETTE trial, evaluating pirfenidone in patients with HF with preserved ejection fraction, have been very recently announced. This review summarizes the data about pirfenidone as a potential cardioprotective treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisPyridonesAnimalsFibrosisHumansMyocytes, Cardiac

Stichwörter der Autor:innen

FibrosisInflammationMyocardial diseasesPirfenidone

Substanzen

Pyridonespirfenidone

Autor:innen und Institutionen

  • Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy. a.aimo@santannapisa.it.
  • Fondazione Toscana Gabriele Monasterio, Pisa, Italy. a.aimo@santannapisa.it.
  • Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias I Pujol, Badalona, Spain.
  • Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.
  • Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
  • CIBERCV, Instituto de Salud Carlos III, Madrid, Spain.

ORCID-Profile: Alberto Aimo

Förderung

  • Scuola Superiore Sant'Anna

Zitieren

APA

Aimo, A., Spitaleri, G., Panichella, G., Lupón, J., Emdin, M., & Bayes-Genis, A. (2022). Pirfenidone as a novel cardiac protective treatment. Heart Failure Reviews, 27(2), 525-532. https://doi.org/10.1007/s10741-021-10175-w

Vancouver

Aimo A, Spitaleri G, Panichella G, Lupón J, Emdin M, Bayes-Genis A. Pirfenidone as a novel cardiac protective treatment. Heart Failure Reviews. 2022;27(2):525-532. doi:10.1007/s10741-021-10175-w

BibTeX
@article{Aimo2022,
  author = {Aimo, Alberto and Spitaleri, Giosafat and Panichella, Giorgia and Lupón, Josep and Emdin, Michele and Bayes-Genis, Antoni},
  title = {Pirfenidone as a novel cardiac protective treatment},
  journal = {Heart Failure Reviews},
  year = {2022},
  volume = {27},
  number = {2},
  pages = {525--532},
  doi = {10.1007/s10741-021-10175-w}
}
Kostenlos starten →